secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-065611
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports Q1 cash of $78.8M; Phase 3 sarcoidosis data on track for Q3 2025
--------------------------------------------------------------------------------

- Cash, restricted cash and investments at $78.8M as of March 31, 2025; cash runway sufficient for one year after Phase 3 readout.
- Phase 3 EFZO-FIT top-line data (efzofitimod in pulmonary sarcoidosis) expected in Q3 2025; 268 patients enrolled at 85 sites.
- Phase 2 EFZO-CONNECT (SSc-ILD) interim data on skin assessments expected in Q2 2025; up to 25 patients.
- Appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise; 25+ years industry experience.
- R&D expenses $11.8M and G&A $4.0M in Q1 2025; preclinical ATYR2810 data presented at AACR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/0000950170-25-065611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-065611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer